Related Experiment Videos
Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death
1Department of Internal Medicine, Ochsner Clinic, New Orleans, Louisiana 70121.
Insights
Left ventricular hypertrophy (LVH), a condition linked to hypertension, increases cardiovascular risks. Reducing LVH with antihypertensive therapy can suppress ventricular dysrhythmias and potentially lower associated mortality.
Area of Science:
- Cardiology
- Hypertension Research
- Clinical Medicine
Background:
- Left ventricular hypertrophy (LVH) is a common consequence of sustained arterial hypertension.
- LVH is a significant independent risk factor for cardiovascular morbidity and mortality.
- LVH can precipitate ventricular dysrhythmias, with links to sudden death.
Purpose of the Study:
- To investigate the relationship between arterial hypertension and LVH.
- To explore the impact of LVH on cardiovascular events.
- To assess the efficacy of antihypertensive therapies in reducing LVH and associated risks.
Main Methods:
- Review of existing literature on LVH and hypertension.
- Analysis of studies correlating blood pressure, LV mass, and cardiovascular outcomes.
- Evaluation of the effects of different antihypertensive drugs on LVH regression.
Main Results:
- A weak correlation exists between spot blood pressure and LV mass.
- LVH is a potent risk factor for cardiovascular morbidity and mortality, independent of blood pressure.
- Antihypertensive therapy can reduce LVH, with varying drug equipotency.
- LVH reduction is associated with suppressed ventricular dysrhythmias and may decrease mortality.
Conclusions:
- Left ventricular hypertrophy is a critical determinant of cardiovascular risk.
- Effective antihypertensive treatment strategies targeting LVH reduction are crucial.
- Reducing LVH may mitigate ventricular dysrhythmias and improve patient outcomes.
Abstract:
Left ventricular hypertrophy (LVH) is a common sequela of sustained arterial hypertension, although the correlation between spot blood pressure measurements and LV mass is not a close one. LVH has been shown to be a powerful blood pressure-independent risk factor for cardiovascular morbidity and mortality. LVH has been shown to trigger or to accelerate ventricular dysrhythmias, although the connection between ventricular dysrhythmias and sudden death is poorly documented. LVH can be reduced by specific antihypertensive therapy; however, not all drugs are equipotent in this regard. A reduction of LVH has been shown to be associated with a suppression of ventricular dysrythmias. Preliminary studies also indicate that the reduction of LVH may reduce its inherent excessive morbidity and mortality.